Abstract
As the cost of psoriasis therapies skyrockets, it becomes increasingly important to find biomarkers that predict which patients will respond to expensive medications. The ability to predict response to a specific therapy is particularly important for medications that are effective in only a small portion of the population. As we develop medications that clear most patients, the need for a predictive biomarker diminishes. Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of drugs continues to rise.
| Original language | English |
|---|---|
| Pages (from-to) | 2339-2340 |
| Number of pages | 2 |
| Journal | Journal of Investigative Dermatology |
| Volume | 136 |
| Issue number | 12 |
| DOIs |
|
| State | Published - 1 Dec 2016 |
Fingerprint
Dive into the research topics of 'Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver